Home › NDC Lookup › RxCUI directory › RxCUI 597730

Lopinavir 200 MG / ritonavir 50 MG Oral Tablet — RxCUI 597730

RxNorm drug concept · Semantic clinical drug
RxCUI 597730 Semantic clinical drug · SCD ● Current RxNorm concept 11 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI597730
Official nameLopinavir 200 MG / ritonavir 50 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped11
Package NDCs mapped15
Reported Medicaid activity (SDUD)282 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lopinavir and Ritonavir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lopinavir and ritonavir attacks HIV at a specific step in its life cycle. The virus needs an enzyme called protease to cut proteins into shapes it can use to build new, infectious...
  • What exactly is this medication doing for my HIV?
  • If you're taking the tablet form (Kaletra tablets or the generic lopinavir and ritonavir tablets), you can take it with or without food — that's flexible. Just be sure to swallow t...
  • Does it matter when I take my tablets — do I have to take them with food?
📖 Read our full Lopinavir and Ritonavir guide →

🕸️ Concept Web — How Lopinavir 200 MG / ritonavir 50 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lopinavir 200 MG / ritonavir 50 MG Oral Tablet RxCUI 597730

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Lopinavir 195088
    • Ritonavir 85762
    • Lopinavir / ritonavir 284640
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kaletra 284756
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lopinavir / ritonavir Oral Tablet 597729
    • Lopinavir / ritonavir Oral Product 1163858
    • Lopinavir / ritonavir Pill 1163859
    • Lopinavir / ritonavir Oral Tablet [Kaletra] 847740
    • Kaletra Oral Product 1168546
    • Kaletra Pill 1168549
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lopinavir 200 MG SCDC · 597727
  • Ritonavir 50 MG SCDC · 597728
  • Lopinavir / ritonavir Oral Tablet SCDF · 597729
  • Lopinavir / ritonavir Oral Product SCDG · 1163858
  • Lopinavir / ritonavir Pill SCDG · 1163859

Brand-Name Concepts

📦 FDA Products & Package NDCs

11 products · 15 package NDCs
15 package NDCs map to RxCUI 597730 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-0522-60 60 TABLET, FILM COATED in 1 BOTTLE (0074-0522-60) Kaletra AbbVie Inc. 2010-06-18
00074-3008-60 60 TABLET, FILM COATED in 1 BOTTLE (0074-3008-60) Kaletra AbbVie Inc. 2024-06-14
00074-3956-46 1 BOTTLE in 1 CARTON (0074-3956-46) / 160 mL in 1 BOTTLE Kaletra AbbVie Inc. 2010-06-18
00074-4014-12 120 TABLET, FILM COATED in 1 BOTTLE (0074-4014-12) Kaletra AbbVie Inc. 2024-02-15
00074-6799-22 120 TABLET, FILM COATED in 1 BOTTLE (0074-6799-22) Kaletra AbbVie Inc. 2010-06-18
31722-0556-12 120 TABLET, FILM COATED in 1 BOTTLE (31722-556-12) Lopinavir and ritonavir Camber Pharmaceuticals, Inc. 2021-06-07
31722-0556-31 8 BLISTER PACK in 1 CARTON (31722-556-31) / 10 TABLET, FILM... Lopinavir and ritonavir Camber Pharmaceuticals, Inc. 2021-06-07
31722-0556-32 8 BLISTER PACK in 1 CARTON (31722-556-32) / 10 TABLET, FILM... Lopinavir and ritonavir Camber Pharmaceuticals, Inc. 2021-06-07
31722-0556-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-556-60) Lopinavir and ritonavir Camber Pharmaceuticals, Inc. 2021-06-07
31722-0603-12 120 TABLET, FILM COATED in 1 BOTTLE (31722-603-12) Lopinavir and ritonavir Camber Pharmaceuticals, Inc. 2021-06-07
31722-0603-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-603-60) Lopinavir and ritonavir Camber Pharmaceuticals, Inc. 2021-06-07
33342-0163-09 60 TABLET, FILM COATED in 1 BOTTLE (33342-163-09) Lopinavir and Ritonavir Macleods Pharmaceuticals Limited 2024-07-25
33342-0164-09 60 TABLET, FILM COATED in 1 BOTTLE (33342-164-09) Lopinavir and Ritonavir Macleods Pharmaceuticals Limited 2024-07-25
42385-0933-60 60 TABLET, FILM COATED in 1 BOTTLE (42385-933-60) Lopinavir and Ritonavir Laurus Labs Limited 2022-03-22
42385-0934-12 120 TABLET, FILM COATED in 1 BOTTLE (42385-934-12) Lopinavir and Ritonavir Laurus Labs Limited 2022-03-22
Observed labelers: Camber Pharmaceuticals, Inc. (6) · AbbVie Inc. (5) · Laurus Labs Limited (2) · Macleods Pharmaceuticals Limited (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.